Hepatic adverse events (AEs) in the form of elevation of alanine aminotransferase (ALT)/aspartate transaminase (AST) and/or hyperbilirubinemia are of particular concern to clinicians due to the worry of autoimmune hepatitis.3 This evidence concerns the gene GPT and autoimmune hepatitis.